Search - tctmd.com

Displaying 481 - 491 of 491

Sort: Relevancy | Date

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Presentation TVT 2012

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Presenter: Gregg Stone

June 05, 2012

Presentation TVT 2012

The Evolving Standard of Care: Atrial Fibrillation Ablation

Presenter: Shephal Doshi

June 05, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Presenter: Robert G. Hart

April 27, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Presentation

The Clinical Impact of Incomplete LAA Closure With the Watchman Device in Patients With A-fib

Presenter: J. Viles-Gonzalez

February 26, 2012

Presentation TCT 2012

The New 320-Row Computed Tomography With Lower Radiation Exposure to Rule-out Coronary Artery Disease in Patients with Atrial Fibrillation

Presenter: Francesco Pelliccia, Antonietta Evangelista, Amedeo Pergolini, Vincenzo Pasceri, Nicola Viceconte, Giuseppe Pannarale, Salvatore Varrica, Susanna Romitelli, Massimo Pellegrini, Carlo Gaudio

January 03, 2012

Advertisement

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

The Evolving Standard of Care: Atrial Fibrillation Ablation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

The Clinical Impact of Incomplete LAA Closure With the Watchman Device in Patients With A-fib

The New 320-Row Computed Tomography With Lower Radiation Exposure to Rule-out Coronary Artery Disease in Patients with Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content